WOMAC MCII Pain subscale (reduction in knee pain by 20%) ‐ Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d · patients with osteoarthritis
Chondroitin leads to higher WOMAC MCII Pain subscale (reduction in knee pain by 20%) ‐ Long‐term… compared with placebo (high certainty).
1 finding from 1 review
Composite Measure of Pain, Function and Disability as · patients with osteoarthritis
1 finding from 1 review
Radiographic Outcome: Reduction in Minimum Joint Space Width (JSW) in mm ‐ Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d Scale: millimeters (smaller decrease in reduction in minimum joint space width is better) · patients with osteoarthritis
1 finding from 1 review
Withdrawals due to adverse events · patients with osteoarthritis
Chondroitin showed no clear difference in withdrawals due to adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Number of serious adverse events · patients with osteoarthritis
Chondroitin probably leads to lower number of serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Pain (short‐ and long‐term) Scale from 0 to 100 mm (lower is better) · patients with osteoarthritis
1 finding from 1 review
WOMAC MCII Pain subscale (reduction in knee pain by 20%) ‐ Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d · patients with osteoarthritis
Chondroitin with or without glucosamine leads to higher WOMAC MCII Pain subscale (reduction in knee pain by 20%) Long‐term… compared with placebo/control (high certainty).
1 finding from 1 review
ACR 50% improvement · patients with rheumatoid arthritis
Rituximab (2 x 1000 mg) plus methotrexate probably leads to higher clinical improvement American College of Rheumatology 50%… compared with methotrexate monotherapy (moderate certainty).
1 finding from 1 review
Clinical remission · patients with rheumatoid arthritis
Rituximab (2 x 1000 mg) plus methotrexate showed no clear difference in clinical remission (Disease Activity Score‐28 joint count < 2.6)… compared with methotrexate monotherapy (moderate certainty).
1 finding from 1 review
Physical function · patients with rheumatoid arthritis
Rituximab (2 x 1000 mg) plus methotrexate leads to higher physical function (HAQ‐DI MCID = ‐0.22) Analysis 1.10 compared with methotrexate monotherapy (high certainty).
1 finding from 1 review
No radiographic progression in total Genant‐modified Sharp score (range 0 to 290) Analysis 1.21 · patients with rheumatoid arthritis
Rituximab (2 x 1000 mg) plus methotrexate showed no clear difference in no radiographic progression in total Genant‐modified Sharp score… compared with methotrexate monotherapy (moderate certainty).
1 finding from 1 review
Health‐related quality of life · patients with rheumatoid arthritis
Rituximab (2 x 1000 mg) plus methotrexate leads to higher health‐related quality of life compared with methotrexate monotherapy (high certainty).
1 finding from 1 review
Discontinuation of medication due to adverse events · patients with rheumatoid arthritis
Rituximab (2 x 1000 mg) plus methotrexate showed no clear difference in discontinuations due to adverse events Analysis 6.3 compared with methotrexate monotherapy (moderate certainty).
1 finding from 1 review
Serious adverse events Analysis 11.2 · patients with rheumatoid arthritis
Rituximab (2 x 1000 mg) plus methotrexate showed no clear difference in serious adverse events Analysis 11.2 compared with methotrexate monotherapy (moderate certainty).
1 finding from 1 review
Outcomesa · 125 hands in 121 participants with Dupuytren's disease of the fingers for early outcomes (van Rijssen 2006)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrence · 93 participants (van Rijssen 2012a)
1 finding from 1 review
Major outcome group 5 (adverse effects)d · 93 participants (van Rijssen 2012a)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
PEM hand function score at 3 years Major outcome group 1 (hand function) (scores between 0 and 77, where 0 represents no impairment in hand function and 77 represents maximum impairment in hand function) · 79 participants (Ullah 2009)
1 finding from 1 review
Major outcome group 2 (patient satisfaction and other PROM) · 79 participants (Ullah 2009)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Correction of MCPJ and PIPJ deformities at 2 weeks Major outcome group 3 (early angular outcomes) · 79 participants (Ullah 2009)
1 finding from 1 review